Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies (Review)

Michele Maio, Lorelei Irina Brasoveanu, Sandra Coral, Luca Sigalotti, Elda Lamaj, Aldo Gasparollo, Alberto Visintin, Maresa Altomonte, Ester Fonsatti

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Protectin (CD59) is a glycosyl-phosphatidylinositol-anchored cell membrane glycoprotein, ubiquitously expressed, though to a different extent, on benign and malignant cells. CD59 inhibits complement (C)-mediated lysis of target cells by preventing the formation of the membrane attack complex, in the terminal step of C-activation. Recent experimental evidence demonstrates that CD59 is the main restriction factor of C-mediated lysis of malignant cells of different histotype. Additionally, a soluble form of CD59, that retains its anchoring ability and functional properties, has been most recently identified in body fluids and in culture supernatants of different malignant cells. In view of its functional role, CD59 may protect neoplastic cells from C-mediated lysis, contributing to their escape from innate C- control and to tumor progression; additionally, the expression of CD59 by neoplastic cells may contribute to impair the therapeutic efficacy of C- activating monoclonal antibodies (mAb) directed to tumor-associated antigens. In the light of the functional role of CD59, this review focuses on the structural features, tissue distribution and regulation of the expression of CD59 in malignant tissues, and on the foreseeable application(s) of CD59 to improve the therapeutic efficacy of clinical approaches of humoral immunotherapy with C-activating mAb in human malignancies.

Original languageEnglish
Pages (from-to)305-318
Number of pages14
JournalInternational Journal of Oncology
Volume13
Issue number2
Publication statusPublished - Aug 1998

Fingerprint

CD59 Antigens
Immunotherapy
Neoplasms
Monoclonal Antibodies
Complement Membrane Attack Complex
Glycosylphosphatidylinositols
Membrane Glycoproteins
Body Fluids
Neoplasm Antigens
Tissue Distribution
Cell Membrane
Therapeutics

Keywords

  • CD59
  • Complement
  • Glycosyl phosphatidylinositol anchor
  • Immunotherapy
  • Protectin
  • Solid tumors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Maio, M., Brasoveanu, L. I., Coral, S., Sigalotti, L., Lamaj, E., Gasparollo, A., ... Fonsatti, E. (1998). Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies (Review). International Journal of Oncology, 13(2), 305-318.

Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies (Review). / Maio, Michele; Brasoveanu, Lorelei Irina; Coral, Sandra; Sigalotti, Luca; Lamaj, Elda; Gasparollo, Aldo; Visintin, Alberto; Altomonte, Maresa; Fonsatti, Ester.

In: International Journal of Oncology, Vol. 13, No. 2, 08.1998, p. 305-318.

Research output: Contribution to journalArticle

Maio, M, Brasoveanu, LI, Coral, S, Sigalotti, L, Lamaj, E, Gasparollo, A, Visintin, A, Altomonte, M & Fonsatti, E 1998, 'Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies (Review)', International Journal of Oncology, vol. 13, no. 2, pp. 305-318.
Maio, Michele ; Brasoveanu, Lorelei Irina ; Coral, Sandra ; Sigalotti, Luca ; Lamaj, Elda ; Gasparollo, Aldo ; Visintin, Alberto ; Altomonte, Maresa ; Fonsatti, Ester. / Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies (Review). In: International Journal of Oncology. 1998 ; Vol. 13, No. 2. pp. 305-318.
@article{5dd98947d549409e9ede2e871ad00cda,
title = "Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies (Review)",
abstract = "Protectin (CD59) is a glycosyl-phosphatidylinositol-anchored cell membrane glycoprotein, ubiquitously expressed, though to a different extent, on benign and malignant cells. CD59 inhibits complement (C)-mediated lysis of target cells by preventing the formation of the membrane attack complex, in the terminal step of C-activation. Recent experimental evidence demonstrates that CD59 is the main restriction factor of C-mediated lysis of malignant cells of different histotype. Additionally, a soluble form of CD59, that retains its anchoring ability and functional properties, has been most recently identified in body fluids and in culture supernatants of different malignant cells. In view of its functional role, CD59 may protect neoplastic cells from C-mediated lysis, contributing to their escape from innate C- control and to tumor progression; additionally, the expression of CD59 by neoplastic cells may contribute to impair the therapeutic efficacy of C- activating monoclonal antibodies (mAb) directed to tumor-associated antigens. In the light of the functional role of CD59, this review focuses on the structural features, tissue distribution and regulation of the expression of CD59 in malignant tissues, and on the foreseeable application(s) of CD59 to improve the therapeutic efficacy of clinical approaches of humoral immunotherapy with C-activating mAb in human malignancies.",
keywords = "CD59, Complement, Glycosyl phosphatidylinositol anchor, Immunotherapy, Protectin, Solid tumors",
author = "Michele Maio and Brasoveanu, {Lorelei Irina} and Sandra Coral and Luca Sigalotti and Elda Lamaj and Aldo Gasparollo and Alberto Visintin and Maresa Altomonte and Ester Fonsatti",
year = "1998",
month = "8",
language = "English",
volume = "13",
pages = "305--318",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies (Review)

AU - Maio, Michele

AU - Brasoveanu, Lorelei Irina

AU - Coral, Sandra

AU - Sigalotti, Luca

AU - Lamaj, Elda

AU - Gasparollo, Aldo

AU - Visintin, Alberto

AU - Altomonte, Maresa

AU - Fonsatti, Ester

PY - 1998/8

Y1 - 1998/8

N2 - Protectin (CD59) is a glycosyl-phosphatidylinositol-anchored cell membrane glycoprotein, ubiquitously expressed, though to a different extent, on benign and malignant cells. CD59 inhibits complement (C)-mediated lysis of target cells by preventing the formation of the membrane attack complex, in the terminal step of C-activation. Recent experimental evidence demonstrates that CD59 is the main restriction factor of C-mediated lysis of malignant cells of different histotype. Additionally, a soluble form of CD59, that retains its anchoring ability and functional properties, has been most recently identified in body fluids and in culture supernatants of different malignant cells. In view of its functional role, CD59 may protect neoplastic cells from C-mediated lysis, contributing to their escape from innate C- control and to tumor progression; additionally, the expression of CD59 by neoplastic cells may contribute to impair the therapeutic efficacy of C- activating monoclonal antibodies (mAb) directed to tumor-associated antigens. In the light of the functional role of CD59, this review focuses on the structural features, tissue distribution and regulation of the expression of CD59 in malignant tissues, and on the foreseeable application(s) of CD59 to improve the therapeutic efficacy of clinical approaches of humoral immunotherapy with C-activating mAb in human malignancies.

AB - Protectin (CD59) is a glycosyl-phosphatidylinositol-anchored cell membrane glycoprotein, ubiquitously expressed, though to a different extent, on benign and malignant cells. CD59 inhibits complement (C)-mediated lysis of target cells by preventing the formation of the membrane attack complex, in the terminal step of C-activation. Recent experimental evidence demonstrates that CD59 is the main restriction factor of C-mediated lysis of malignant cells of different histotype. Additionally, a soluble form of CD59, that retains its anchoring ability and functional properties, has been most recently identified in body fluids and in culture supernatants of different malignant cells. In view of its functional role, CD59 may protect neoplastic cells from C-mediated lysis, contributing to their escape from innate C- control and to tumor progression; additionally, the expression of CD59 by neoplastic cells may contribute to impair the therapeutic efficacy of C- activating monoclonal antibodies (mAb) directed to tumor-associated antigens. In the light of the functional role of CD59, this review focuses on the structural features, tissue distribution and regulation of the expression of CD59 in malignant tissues, and on the foreseeable application(s) of CD59 to improve the therapeutic efficacy of clinical approaches of humoral immunotherapy with C-activating mAb in human malignancies.

KW - CD59

KW - Complement

KW - Glycosyl phosphatidylinositol anchor

KW - Immunotherapy

KW - Protectin

KW - Solid tumors

UR - http://www.scopus.com/inward/record.url?scp=0031821575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031821575&partnerID=8YFLogxK

M3 - Article

C2 - 9664126

AN - SCOPUS:0031821575

VL - 13

SP - 305

EP - 318

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 2

ER -